Navigation Links
Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Date:7/22/2008

se I efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.

About Green Cross Corporation

Green Cross is a leader in the Korean biotechnology and pharmaceutical industries. Green Cross is now an internationally recognized biotechnology company developing several vaccines and therapeutic proteins. Green Cross will become the only seasonal influenza vaccine manufacturer in South Korea and also is developing avian influenza vaccine. In its vaccine business, Green Cross has successfully developed one of the earliest vaccines against Hepatitis B (Hepavax), the first Epidemic Hemorrhagic Fever vaccine and the world's second chicken pox vaccine. Green Cross is developing anticancer drugs such as Greenstatin (anti-angiogenic peptide) and modified PEG-G-CSF for neutropenia.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
2. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
11. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... York , July 11, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... To Be Presented in a Poster Session at the ... -SAN FRANCISCO, March 6 Galderma Laboratories, L.P. today ... of plaque psoriasis using Clobex (R) (clobetasol propionate) ... 3mcg/g. The results of an interim analysis of ...
... Germany, March 6 B-R-A-H-M-S,Aktiengesellschaft today announced it ... Drug Administration (FDA) to market its patented B-R-A-H-M-S,MR-proANP ... Natriuretic Peptide (ANP) is predominantly produced in the ... natriuretic peptides in the,circulation. ANP is involved in ...
Cached Medicine Technology:Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 2Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 3Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 4FDA Submission of B-R-A-H-M-S MR-proANP Kryptor 2
(Date:7/14/2014)... Rock Hill, SC (PRWEB) July 14, 2014 ... vegetables, but a study by the School of Public ... fruit and vegetable consumption had a near-zero effect on weight ... foods must be combine with some form of portion ... is a method of monitoring portions and controlling how much ...
(Date:7/14/2014)... Sometimes, thinking “inside the box” can be ... first product release, Joyboxx™ - The world’s only hygienic ... , Inventor and CEO, Deborah Semer began designing a ... solution for their ‘toys’ after she realized no such ... , Semer met 30-year industry veteran Phyllis Heppenstall, the ...
(Date:7/14/2014)... EurekaMag.com has newly published results of 64,900 ... disease that ranges in severity from a mild ... illness that attacks the liver. An estimated 3.2 million ... virus infection of which approximately 80% of people develop ... all studies on Hepatitis C , the Life, Earth ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 "Medical devices, ... one of us. The Tri-Valley is a star when ... based in the region are working on amazing products ... the face of medicine," according to Dale Kaye CEO ... To showcase some of the brilliant minds and businesses ...
(Date:7/14/2014)... WI (PRWEB) July 14, 2014 Doctor ... announced the launch of their new company website. The ... valuable free information on chiropractic marketing. It's also a ... that Inception has to offer. , When contacted at ... the newest version of our main website. Our site ...
Breaking Medicine News(10 mins):Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4Health News:Doctor Mike Hamilton From Inception Chiropractic Websites Announces the Launch of Their New Website 2
... (CDC)’s Morbidity and Mortality Weekly Report, West Virginia has a ... the U.S. Virgin Islands has the lowest. ... data collected through the Behavioral Risk Factor Surveillance System, a ... health departments. ,Levels of coronary heart disease, ...
... including four doctors have been accused of cheating insurance ... involved in giving allergy shots to many// patients without ... ,Patients were also not informed about the risk factors ... for testing procedures were not sent to the lab ...
... Genetic factors play an important role in the ... University School of Medicine in St. Louis.// ... genetic variations can influence smoking behaviors and contribute ... ,Scientists suggest that these smoking-related genes may ...
... to make many plastics found in food storage containers ... according to a recent study by Yale School of ... Taylor, M.D., associate professor in the Department of Obstetrics, ... study shows that BPA changes the expression of key ...
... risk of rash, leading to treatment discontinuation or interruption//, ... research published in the January edition of HIV Medicine. ... once daily were more likely to experience liver complications ... For these reasons, the authors conclude that once-daily nevirapine ...
... consumers not to purchase, or use, Wild Kitty Cat Food ... monitoring activities, FDA collected and analyzed a sample of frozen ... product. Cats and other pets consuming this food may become ... if they handle or ingest this cat food, touch pets ...
Cached Medicine News:Health News:Genes for Nicotine Dependence Identified 2Health News:Genes for Nicotine Dependence Identified 3Health News:Genes for Nicotine Dependence Identified 4Health News:Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose 2Health News:Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose 3Health News:Consumers Warned of Using Cat Food Due to Salmonella Contamination 2
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... Penetration Steered Linear Peripheral Vascular transducer, with ... MHz. It is our newest vascular ... 4 different settings to optimize imaging of ... color and Doppler sensitivity of this transducer ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
... The UST-MC11-8731 is a perfect alternative ... are used to seeing more of a ... of the transducer in the hand., This ... shaped convex intraoperative transducer. The UST-MC11-8731 nestles ...
Medicine Products: